CYP19A1 Antibody

What is CYP19A1 and why is it significant in research?

CYP19A1, also known as aromatase, is a key enzyme responsible for the biosynthesis of estrogens from androgenic precursors. Its significance in research stems from its crucial role in hormone-dependent processes and various pathological conditions. Recent studies have demonstrated that CYP19A1 is overexpressed in colorectal cancer (CRC) tissues and cell lines compared to normal controls, suggesting its involvement in cancer development . Additionally, CYP19A1 amplification has been identified as an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer . The enzyme's role in regulating mitochondrial function and chemoresistance makes it an important target for cancer research, particularly in studying therapeutic resistance mechanisms.

How do CYP19A1 antibodies function in detecting the target protein?

CYP19A1 antibodies operate by specifically recognizing and binding to epitopes on the aromatase enzyme. These antibodies typically target unique amino acid sequences that are accessible in the protein's tertiary structure. When employing CYP19A1 antibodies in research, it's essential to understand that their efficacy depends on the preservation of these epitopes during sample preparation.

For detection methodologies:

• In immunohistochemistry and immunofluorescence techniques, CYP19A1 antibodies bind to their target in fixed tissues or cells, allowing visualization through direct or indirect labeling systems.

• For western blotting, these antibodies recognize denatured CYP19A1 protein separated by electrophoresis.

• In immunoprecipitation, they can pull down the native protein from complex mixtures.

Research has demonstrated successful application of CYP19A1 antibodies in detecting the enzyme's localization to mitochondria in colorectal cancer cells, providing valuable insights into its subcellular distribution and potential function .

What are the primary research applications of CYP19A1 antibodies?

CYP19A1 antibodies serve multiple critical research applications:

How can researchers validate the specificity of CYP19A1 antibodies?

Validating CYP19A1 antibody specificity is crucial for obtaining reliable research results. A multi-faceted approach includes:

• Positive and negative controls:

  • Positive: Using tissues/cells known to express CYP19A1 (e.g., placenta, ovary, or CYP19A1-overexpressing cell lines)

  • Negative: Using CYP19A1 knockout cells as demonstrated in recent research where CRISPR/Cas9 was used to generate CYP19A1 knockout CRC cell lines

• Western blot analysis: Confirming a single band of the appropriate molecular weight (~58 kDa for CYP19A1)

• Peptide competition assay: Pre-incubating the antibody with a blocking peptide containing the target epitope should eliminate specific binding

• Knockdown verification: Testing the antibody in samples where CYP19A1 has been silenced through siRNA or CRISPR technologies

• Cross-validation with multiple antibodies: Using different antibodies targeting distinct epitopes of CYP19A1

• Mass spectrometry verification: Following immunoprecipitation with the CYP19A1 antibody, mass spectrometry can confirm the identity of the pulled-down protein

Researchers have successfully employed knockout validation strategies to confirm CYP19A1 antibody specificity in colorectal cancer studies, demonstrating decreased signal in CYP19A1 knockout cells compared to wild-type controls .

What techniques can effectively measure CYP19A1 enzymatic activity in correlation with antibody-detected expression?

Measuring CYP19A1 enzymatic activity alongside antibody-detected protein expression provides a comprehensive understanding of aromatase function. Effective techniques include:

• Radiometric assays: Measuring the conversion of radiolabeled androgen substrates to estrogens

• Fluorometric assays: Using fluorescent substrate analogs that change properties upon conversion

• Liquid chromatography-mass spectrometry (LC-MS): Directly measuring estrogen production from androgen precursors

• ELISA-based activity assays: Quantifying estradiol production in cell or tissue samples

• Bioluminescent assays: Utilizing reporter constructs that respond to estrogen production

For correlation analysis:

• Perform parallel experiments measuring protein expression via CYP19A1 antibodies (western blot, immunohistochemistry) and enzymatic activity

• Plot correlation curves between expression and activity levels

• Investigate discrepancies that may indicate post-translational regulation

Recent research has demonstrated that exogenous expression of wild-type CYP19A1, but not catalytically inactive mutants (D309N, Y361F), restores estrogen production in CYP19A1 knockout cells, confirming the relationship between protein expression and enzymatic function .

How should researchers optimize immunohistochemistry protocols for CYP19A1 detection in different tissue types?

Optimizing immunohistochemistry (IHC) protocols for CYP19A1 detection requires systematic refinement of multiple parameters:

Tissue Preparation Variables:

• Fixation method: Formalin fixation time (typically 24-48 hours) is critical as overfixation can mask epitopes

• Antigen retrieval: Test multiple methods (heat-induced in citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Section thickness: Optimal thickness is typically 4-5 μm

Protocol Optimization:

• Antibody dilution titration: Test serial dilutions (typically 1:100 to 1:1000) to determine optimal concentration

• Incubation conditions: Compare overnight incubation at 4°C versus 1-2 hours at room temperature

• Detection system selection: DAB-based versus fluorescent detection, with consideration of signal amplification systems for low-abundance targets

• Counterstaining intensity: Adjust to provide contrast without obscuring specific staining

Tissue-Specific Modifications:

• Colorectal tissue: May require extended antigen retrieval due to dense extracellular matrix

• Breast tissue: Often benefits from lower antibody concentrations due to potentially higher endogenous expression

• Archived samples: May need additional antigen retrieval steps to overcome extended fixation effects

Validation Approach:

• Include positive control tissues known to express CYP19A1

• Use CYP19A1 knockout or siRNA-treated samples as negative controls

• Score staining patterns with attention to subcellular localization (cytoplasmic versus mitochondrial)

A comprehensive optimization matrix testing these variables will help establish reliable IHC protocols for consistent CYP19A1 detection across different tissue types.

How can CYP19A1 antibodies be used to investigate its role in chemoresistance mechanisms?

Designing experiments to investigate CYP19A1's role in chemoresistance requires a multifaceted approach using CYP19A1 antibodies:

Experimental Design Strategy:

• Expression correlation studies:

  • Compare CYP19A1 protein levels between chemosensitive and chemoresistant cell lines/patient samples using western blotting and immunohistochemistry

  • Perform quantitative image analysis to establish statistical correlations between CYP19A1 expression and drug resistance phenotypes

• Functional manipulation experiments:

  • Generate CYP19A1 knockout cell lines using CRISPR/Cas9 technology

  • Create CYP19A1-overexpressing cells through transfection/transduction

  • Assess changes in chemosensitivity through dose-response curves and calculate IC50 values

  • Use CYP19A1 antibodies to confirm protein depletion or overexpression

• Mechanistic investigations:

  • Employ immunofluorescence with mitochondrial markers to assess CYP19A1 localization in resistant versus sensitive cells

  • Use proximity ligation assays with CYP19A1 antibodies to identify protein-protein interactions that might mediate resistance

  • Perform chromatin immunoprecipitation followed by sequencing (ChIP-seq) to identify estrogen-responsive genes involved in resistance mechanisms

• Translational validation:

  • Apply CYP19A1 immunohistochemistry to patient cohorts with known treatment outcomes

  • Develop scoring systems and correlate with clinical data on chemotherapy response and survival

Recent research demonstrated that CYP19A1 knockout significantly suppressed mitochondrial respiration and reduced complex I activity in chemoresistant colorectal cancer cells, effectively reversing their chemoresistance . Conversely, overexpression of CYP19A1 or treatment with estradiol increased the tolerance of parental cells to chemotherapeutic drugs .

What methodologies allow researchers to study the relationship between CYP19A1 localization and function?

Studying the relationship between CYP19A1 localization and function requires sophisticated methodological approaches:

Subcellular Fractionation and Analysis:

• Perform subcellular fractionation to isolate mitochondria, endoplasmic reticulum, and cytosolic fractions

• Use western blotting with CYP19A1 antibodies to quantify protein distribution across fractions

• Include fraction-specific markers (e.g., VDAC for mitochondria, calnexin for ER) to confirm separation quality

Advanced Microscopy Techniques:

• Confocal microscopy with co-localization analysis:

  • Double immunofluorescence staining with CYP19A1 antibodies and organelle markers (e.g., MitoTracker)

  • Calculate Pearson's correlation coefficients to quantify co-localization

• Super-resolution microscopy:

  • Structured illumination microscopy (SIM) or stochastic optical reconstruction microscopy (STORM) for nanoscale localization

  • Precise mapping of CYP19A1 within mitochondrial subcompartments

Functional Correlation Studies:

• Site-directed mutagenesis:

  • Generate CYP19A1 constructs with mutations in putative localization signals

  • Express in CYP19A1 knockout cells and assess localization using antibodies

  • Correlate changes in localization with alterations in function

• Organelle-targeted CYP19A1:

  • Create fusion constructs with specific organelle targeting sequences

  • Force localization to different compartments and assess functional consequences

• In situ activity assays:

  • Develop proximity-based reporters of aromatase activity

  • Correlate local estrogen production with CYP19A1 localization

Research has confirmed that CYP19A1 localizes to mitochondria in colorectal cancer cells through immunofluorescence staining showing clear colocalization with MitoTracker . This mitochondrial localization appears functionally significant, as CYP19A1 regulates mitochondrial function through its enzymatic activity and estrogen biosynthesis .

How can researchers integrate CYP19A1 antibody data with genomic and transcriptomic analyses?

Integrating CYP19A1 antibody data with genomic and transcriptomic analyses creates a comprehensive multi-omics approach:

Integration Methodologies:

Bioinformatic Tools and Resources:

• The Cancer Genome Atlas (TCGA) database for validation and expansion of findings

• cBioPortal for exploring genomic alterations in relation to protein expression

• R packages like "DESeq2" for differential expression analysis and "survival" for outcome analysis

How should researchers troubleshoot non-specific binding or background issues with CYP19A1 antibodies?

Systematic troubleshooting of non-specific binding and background issues with CYP19A1 antibodies requires a methodical approach:

Common Problems and Solutions:

Validation Approaches:

• Absorption controls: Pre-incubate CYP19A1 antibody with immunizing peptide before application

• Isotype controls: Use non-specific IgG from the same species at equivalent concentration

• Knockout/knockdown validation: Test antibody specificity in CYP19A1-depleted samples

• Secondary-only controls: Omit primary antibody to assess secondary antibody specificity

• Cross-antibody validation: Compare staining patterns with multiple CYP19A1 antibodies targeting different epitopes

Optimization Matrix for Western Blot Background Reduction:

When testing new applications or sample types, systematic optimization of these parameters can resolve most non-specific binding issues with CYP19A1 antibodies.

How can researchers reconcile discrepancies between CYP19A1 mRNA expression and protein detection?

Reconciling discrepancies between CYP19A1 mRNA expression and protein detection requires systematic investigation of multiple biological and technical factors:

Biological Explanations for Discrepancies:

• Post-transcriptional regulation:

  • Investigate microRNA regulation of CYP19A1 mRNA using prediction algorithms and validation experiments

  • Assess mRNA stability through actinomycin D chase experiments

  • Examine alternative splicing patterns that might affect antibody recognition sites

• Post-translational modifications:

  • Evaluate protein stability using cyclohexamide chase assays

  • Investigate ubiquitination and proteasomal degradation pathways

  • Consider phosphorylation or other modifications that might affect antibody binding

• Functional threshold effects:

  • Determine minimum protein expression required for detectable enzymatic activity

  • Assess whether estrogen production correlates better with mRNA or protein levels

Technical Approaches to Address Discrepancies:

• Multi-method validation:

  • Compare results from different protein detection methods (western blot, immunohistochemistry, ELISA)

  • Employ multiple antibodies targeting different CYP19A1 epitopes

  • Use absolute quantification methods for both mRNA (digital PCR) and protein (MRM mass spectrometry)

• Time-course analyses:

  • Measure both mRNA and protein at multiple time points to detect temporal relationships

  • Account for differences in mRNA versus protein half-life

• Single-cell analyses:

  • Perform single-cell RNA-seq paired with single-cell western blotting or mass cytometry

  • Determine if population heterogeneity explains bulk measurement discrepancies

Analysis Framework:

What approaches help interpret contradictory results between different antibody-based detection methods?

Interpreting contradictory results between different antibody-based detection methods requires a systematic evaluation of methodological differences and biological contexts:

Systematic Comparison Framework:

• Method-specific considerations:

  Detection Method	Key Variables	Potential Limitations
  Western blot	Denaturing conditions, size separation	May miss conformational epitopes, poor for localization
  Immunohistochemistry	Fixation, epitope retrieval, in situ detection	Semi-quantitative, fixation artifacts
  Immunofluorescence	Signal-to-noise ratio, subcellular resolution	Photobleaching, autofluorescence
  Flow cytometry	Single-cell quantification, surface vs. intracellular	Cell permeabilization may affect epitopes
  ELISA	Quantitative, high-throughput	Lacks spatial information, sandwich format requires two distinct epitopes

• Antibody-specific analysis:

  • Compare monoclonal versus polyclonal antibodies targeting CYP19A1

  • Identify exact epitopes recognized by each antibody

  • Assess potential for epitope masking in different sample preparations

• Sample preparation impact:

  • Evaluate effects of different fixatives on epitope preservation

  • Compare fresh versus frozen versus formalin-fixed samples

  • Consider detergent selection for membrane protein extraction

Resolution Strategies:

• Orthogonal validation:

  • Confirm results with functional assays measuring CYP19A1 enzymatic activity

  • Use genetic approaches (siRNA, CRISPR) to validate antibody specificity

  • Apply mass spectrometry-based proteomics for antibody-independent verification

• Concordance analysis:

  • Establish hierarchical decision tree for interpreting contradictory results

  • Weight results based on method-specific reliability for particular applications

  • Consider biological context (e.g., expected expression patterns in specific tissues)

• Combined methodological approach:

  • Apply multiple methods to the same samples to build confidence

  • Develop integrated scoring systems that incorporate results from different methods

  • Establish consensus thresholds for positivity across methods

Research has shown that proper validation with multiple approaches is essential, as demonstrated in studies confirming both the subcellular localization of CYP19A1 to mitochondria through immunofluorescence and its elevated expression through western blotting .

How can CYP19A1 antibodies facilitate investigations into its role in mitochondrial function?

CYP19A1 antibodies can be strategically employed to investigate its mitochondrial functions through several advanced approaches:

Localization and Interaction Studies:

• High-resolution co-localization analysis:

  • Super-resolution microscopy (STORM, PALM, SIM) with CYP19A1 antibodies and mitochondrial markers

  • Electron microscopy with immunogold labeling to determine exact submitochondrial localization

  • Expanded studies beyond colocalization with MitoTracker as demonstrated in recent research

• Proximity-based interaction mapping:

  • Proximity ligation assays (PLA) to identify proteins interacting with CYP19A1 in mitochondria

  • BioID or APEX2 proximity labeling with CYP19A1 fusion proteins, validated by antibody detection

  • Co-immunoprecipitation followed by mass spectrometry to identify the CYP19A1 mitochondrial interactome

Functional Analysis Techniques:

• Mitochondrial subfractionation with CYP19A1 antibodies:

  • Isolate outer membrane, intermembrane space, inner membrane, and matrix fractions

  • Detect CYP19A1 distribution using western blotting

  • Correlate localization with function in each compartment

• In organello activity assays:

  • Isolate intact mitochondria from wild-type and CYP19A1 knockout cells

  • Measure respiratory capacity, membrane potential, and ROS production

  • Correlate with CYP19A1 protein levels detected by antibodies

• Mitochondrial estrogen signaling:

  • Use CYP19A1 antibodies to track enzyme location during estrogen biosynthesis

  • Combine with detection of estrogen receptors in mitochondria

  • Monitor downstream effects on mitochondrial gene expression and function

Experimental Design for Mitochondrial Function Studies:

Research has demonstrated that CYP19A1 regulates mitochondrial function through its enzymatic activity and estrogen biosynthesis, as the expression of wild-type CYP19A1, but not catalytically inactive mutants, rescued impaired mitochondrial respiration in CYP19A1 knockout CRC cells .

What are the best approaches to study CYP19A1 as a predictive biomarker in patient samples?

Developing CYP19A1 as a predictive biomarker requires robust methodological approaches across discovery, validation, and clinical implementation phases:

Biomarker Discovery Phase:

• Retrospective cohort analysis:

  • Perform CYP19A1 immunohistochemistry on archived patient samples with known outcomes

  • Develop standardized scoring systems (H-score, Allred score, or digital quantification)

  • Correlate with response to specific therapies (e.g., chemotherapy)

• Multi-omic integration:

  • Combine CYP19A1 protein data (antibody-based) with genomic and transcriptomic profiles

  • Identify patterns of CYP19A1 alterations associated with treatment responses

  • Develop composite biomarker signatures incorporating multiple parameters

Validation Strategies:

• Technical validation:

  • Establish reproducibility across different laboratories and platforms

  • Determine analytical sensitivity and specificity of CYP19A1 antibody assays

  • Create standard operating procedures for tissue processing and staining

• Clinical validation:

  • Prospective-retrospective studies using samples from completed clinical trials

  • Independent validation cohorts from multiple institutions

  • Blinded assessment by multiple pathologists to establish scoring reliability

Implementation Approaches:

• Standardized assay development:

  • Selection of optimal antibody clone with validated specificity

  • Automated staining platforms for reproducibility

  • Digital pathology algorithms for quantitative assessment

• Clinical utility evaluation:

  • Decision impact studies to assess how CYP19A1 testing affects treatment decisions

  • Health economic analyses to determine cost-effectiveness of testing

  • Integration into treatment guidelines and pathways

Statistical Analysis Framework:

How can researchers investigate the relationship between CYP19A1 gene amplification and protein expression?

Investigating the relationship between CYP19A1 gene amplification and protein expression requires integrated genomic and proteomic approaches:

Genomic Analysis Techniques:

• Copy number detection methods:

  • Fluorescence in situ hybridization (FISH) with CYP19A1-specific probes

  • Comparative genomic hybridization (CGH) arrays

  • Next-generation sequencing-based copy number analysis

  • Digital droplet PCR for precise quantification

• Gene amplification characterization:

  • Determine amplification boundaries and involved genomic regions

  • Assess for co-amplification of neighboring genes

  • Characterize amplification mechanisms (e.g., tandem duplications, extrachromosomal DNA)

Protein Expression Analysis:

• Quantitative protein assessment:

  • Western blotting with CYP19A1 antibodies and densitometry

  • Immunohistochemistry with digital image analysis

  • Quantitative proteomics with labeled reference peptides

  • Reverse phase protein arrays for high-throughput analysis

• Structure-function correlations:

  • Assess whether amplification affects protein structure or post-translational modifications

  • Determine if amplified variants show altered subcellular localization

  • Evaluate enzymatic activity in relation to gene copy number

Integrated Analysis Framework:

Research Applications:

• Resistance mechanism studies:

  • Investigate whether CYP19A1 amplification drives protein overexpression in resistant cells

  • Compare pre- and post-treatment samples to track evolution of amplification

  • Determine whether targeting CYP19A1 can overcome resistance in amplified tumors

• Clinical correlation analyses:

  • Assess whether gene amplification, protein overexpression, or both predict patient outcomes

  • Evaluate which biomarker (DNA or protein) has superior predictive value

  • Develop composite biomarkers incorporating both parameters

Research has shown that acquired CYP19A1 amplification emerges as an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer . This amplification causes increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in decreased sensitivity to aromatase inhibitor treatment .

What emerging technologies might enhance CYP19A1 antibody-based research in the near future?

Several emerging technologies show promise for advancing CYP19A1 antibody-based research:

• Single-cell spatial proteomics:

  • Mass cytometry imaging (IMC) to simultaneously detect CYP19A1 and dozens of other proteins in tissue sections

  • Spatial transcriptomics combined with protein detection to link CYP19A1 mRNA and protein expression at single-cell resolution

  • These approaches would provide unprecedented insights into cell-type specific expression patterns and heterogeneity

• Advanced proximity labeling methods:

  • Next-generation BioID and APEX systems for more precise mapping of the CYP19A1 interactome

  • Split-BioID approaches to capture conditional interactions dependent on specific cellular states

  • These methods would help define the dynamic protein networks involving CYP19A1 in different cellular compartments

• Engineered antibody-based tools:

  • Intracellular antibody fragments (intrabodies) targeting CYP19A1 for live-cell tracking

  • Antibody-based protein degradation technologies (e.g., PROTAC-antibody conjugates) for targeted CYP19A1 degradation

  • These tools would enable more precise manipulation of CYP19A1 in living cells

• Microfluidic antibody platforms:

  • Automated microfluidic immunoassays for high-throughput screening of CYP19A1 expression across patient samples

  • Organ-on-chip systems with integrated antibody detection for real-time monitoring of CYP19A1 in complex tissue models

  • These platforms would facilitate rapid translation of research findings to clinical applications

• Computational antibody enhancement:

  • AI-driven antibody engineering to improve specificity and sensitivity for CYP19A1 detection

  • Machine learning algorithms for automated image analysis of CYP19A1 immunostaining patterns

  • These computational approaches would enhance the reliability and reproducibility of CYP19A1 antibody-based research

These emerging technologies could significantly advance our understanding of CYP19A1's role in cancer biology and treatment resistance, building upon recent discoveries about its involvement in mitochondrial function and chemoresistance .

How should researchers interpret CYP19A1 expression data in the context of sex-specific differences?

Interpreting CYP19A1 expression data requires careful consideration of sex-specific differences at multiple levels:

Analytical Framework:

• Sex-stratified analysis approach:

  • Always analyze male and female samples separately before pooling

  • Test for statistical interactions between sex and CYP19A1 expression in relation to outcomes

  • Consider sex-specific thresholds for "high" versus "low" expression

• Biological context considerations:

  • Acknowledge baseline differences in estrogen levels between males and females

  • Consider tissue-specific expression patterns that may differ by sex

  • Evaluate hormonal status (pre/post-menopausal in females) as a potential modifier

• Methodological considerations:

  • Ensure balanced representation of male and female samples in study design

  • Control for hormonal treatments that might affect CYP19A1 expression

  • Document menstrual/menopausal status in female subjects when applicable

Research Results Interpretation:

Clinical Translation Approach:

• Sex-specific biomarker validation:

  • Develop separate cutoffs for males and females if necessary

  • Validate prognostic/predictive value in sex-stratified cohorts

  • Consider sex-specific therapeutic targeting strategies

• Reporting standards:

  • Always report sex distribution in study populations

  • Include sex as a variable in multivariate analyses

  • Present sex-stratified results even when differences are not statistically significant

What key considerations should inform future research into CYP19A1 inhibition as a therapeutic strategy?

Future research into CYP19A1 inhibition as a therapeutic strategy should address several critical considerations:

Target Validation Strategies:

• Causality assessment:

  • Use inducible CYP19A1 knockdown/knockout systems to directly link enzyme inhibition to therapeutic effects

  • Employ rescue experiments with enzymatically active versus inactive CYP19A1 to confirm mechanism

  • Develop CRISPR screens to identify synthetic lethal interactions with CYP19A1 inhibition

• Patient stratification biomarkers:

  • Identify molecular features that predict response to CYP19A1 inhibition

  • Develop companion diagnostics using validated CYP19A1 antibodies

  • Determine whether CYP19A1 amplification status predicts response

• Resistance mechanism characterization:

  • Map adaptive signaling changes following CYP19A1 inhibition

  • Identify bypass pathways that emerge upon treatment

  • Develop strategies to prevent or overcome resistance

Therapeutic Development Considerations:

• Inhibitor specificity optimization:

  • Design CYP19A1 inhibitors with improved selectivity profiles

  • Develop tissue-specific delivery strategies to minimize off-target effects

  • Create dual-targeting approaches (e.g., CYP19A1 inhibitor conjugated to mitochondria-targeting moieties)

• Combination therapy rationale:

  • Test CYP19A1 inhibitors with chemotherapy based on observed role in chemoresistance

  • Evaluate combinations with mitochondrial complex I inhibitors for synergistic effects

  • Explore rational combinations based on synthetic lethality screens

• Preclinical model development:

  • Establish patient-derived organoids with varying CYP19A1 expression levels

  • Develop genetically engineered models with inducible CYP19A1 expression

  • Create humanized mouse models to better recapitulate estrogen signaling

Translational Research Framework: